Tissue Regenix: On pathway to sustainability

Tissue Regenix Group plc (LON:TRX) is focused on the development and commercialisation of two proprietary processing technologies for the repair of soft tissue (dCELL) and bone (BioRinse). It has a broad portfolio of commercial regenerative medicine products for the biosurgery, orthopaedics and dental markets. 2021 results contained the early benefits of TRX’s strategic activities over the past two years – the focus on commercial relationships, capacity expansion, restructuring to service demand and recovery in elective surgeries. On the basis of continued sales progression, TRX is forecast to become EBITDA-positive in fiscal 2022 and cash-generative in 2023.

  • Strategy: Tissue Regenix is building an international regenerative medicine business around its proprietary technology platforms, underpinned by compelling clinical outcomes. Phase 1 of its manufacturing capacity expansion programme came on-stream in 2021 to satisfy demand from distribution partners for its innovative products.
  • 2021 results: Sales in fiscal 2021 were marginally ahead of our forecasts, at $19.75m, up 20% from $16.47m in 2020. The leverage effect of a strong BioRinse sales performance (+33%) saw a marked reduction in EBIT losses in 2H’21. Gross cash at the period-end was $7.7m.
  • Outlook: The 2021 performance was achieved despite the continuing impact of COVID-19 and some unforeseeable headwinds; this augurs well for the future. Progress is forecast to continue in 2022, resulting in 22% sales growth, which will drive margin expansion towards profitability by the end of 2022.
  • Risks: Early signs of recovery in the number of elective surgeries in the US were dented by the delta variant, and the emergence of another variant remains a possibility. Forecasts suggest that TRX is nearing profitability and cashflow breakeven, which would eliminate any lingering concerns about the need for a capital increase.
  • Investment summary: Tissue Regenix has a broad portfolio of innovative regenerative products that are in demand from surgeons. Completion of Phase 1 of its capacity expansion programme has comforted distribution partners and provided positive momentum. We believe TRX is well-positioned to deliver strong sales growth, which will drive margin expansion and highlight the low rating of the shares. An EV/sales multiple of 4x 2023E sales generates a valuation of $120m/£92m.

DOWNLOAD THE FULL REPORT

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Share on facebook
    Facebook
    Share on twitter
    Twitter
    Share on linkedin
    LinkedIn
    Hardman & Co

    More articles like this

    Hardman & Co

    Tissue Regenix: Faster-than-anticipated recovery

    Tissue Regenix Group plc (LON:TRX) is focused on the development and commercialisation of two proprietary processing technologies for the repair of soft tissue (dCELL) and bone (BioRinse). It has a broad portfolio of marketed regenerative medicine products for

    Hardman & Co

    Tissue Regenix Poised for Growth (Analyst Interview)

    Tissue Regenix Group Plc (LON:TRX) is the topic of conversation when Dr Martin Hall, Analyst at Hardman & Co joined DirectorsTalk. Martin gives us a reminder of what Tissue Regenix does, discusses the poor operating performance, share prices,

    Hardman & Co

    Tissue Regenix: Poised for growth

    Tissue Regenix Group plc (LON:TRX) is focused on the development and commercialisation of two proprietary processing technologies for the repair of soft tissue (dCELL) and bone (BioRinse). It has a broad portfolio of marketed regenerative medicine products for

    Hardman & Co

    Tissue Regenix Group: Funded through to profitability

    Tissue Regenix Group plc (LON:TRX) is focused on the development and commercialisation of two proprietary decellularisation technologies for repair of soft tissue (dCELL) and bone (BioRinse). It has a broad portfolio of approved regenerative medicine products for the

    Hardman & Co

    Tissue Regenix Restructured to satisfy product demand

    Tissue Regenix Group (LON:TRX) has a broad portfolio of regenerative medicine products for the biosurgery, orthopaedics, dental and cardiac markets. It has two proprietary decellularisation technology platforms for repair of soft tissue (dCELL) and bone (BioRinse). Following the

    Hardman & Co

    Tissue Regenix Credit facilities expand cash runway to 2021

    Tissue Regenix (LON: TRX) has a broad portfolio of regenerative medicine products for the biosurgery, orthopaedics, dental and cardiac markets. It has two proprietary decellularisation technology platforms for repair of soft tissue (dCELL) and bone (BioRinse). Following the

    Hardman & Co

    Tissue Regenix Expanded GPO coverage secured

    Tissue Regenix (LON:TRX) has a broad portfolio of regenerative medicine products for the biosurgery, orthopaedics, dental and cardiac markets. It has two proprietary decellularisation technology platforms for the repair of soft tissue (dCELL) and bone (BioRinse). Following its

    Hardman & Co

    Tissue Regenix 2018 in review: foundations laid for osteobiologics

    Tissue Regenix (LON:TRX) has a broad portfolio of regenerative medicine products for the biosurgery, orthopaedics, dental and cardiac markets. It has two proprietary decellularisation technology platforms for the repair of soft tissue (dCELL) and bone (BioRinse). With organic

    Hardman & Co

    Tissue Regenix Group Dual revenue stream growth

    Tissue Regenix Group Plc (LON:TRX) has a broad portfolio of regenerative medicine products developed from decellularised human and porcine soft tissues for the wound care, orthopaedics, and cardiac markets. Since the launch of DermaPure, focus has been on

    Hardman & Co

    Tissue Regenix Group Plc Addressing woundcare in the US

    Tissue Regenix Group Plc (LON:TRX) has a broad portfolio of regenerative medicine products developed from decellularised human and porcine tissues for the wound care, orthopaedics, and cardiac markets. Sales of DermaPure have continued to gain traction in the

    Hardman & Co

    Tissue Regenix Group Plc Major progress towards orthopaedics approvals

    Tissue Regenix Group Plc (LON:TRX) is now in the commercialisation phase having validated its dCELL® technology to produce ‘like-for-like’ tissue specific, structure-preserving scaffolds for use in multiple clinical settings. DermaPure has started well in the US for treating

    Hardman & Co

    Tissue Regenix Group Plc From development – into the commercial world

    Tissue Regenix Group Plc (LON:TRX) is no longer an R&D play. Its dCELL® technology enables production of ‘like-for-like’ tissue specific, structure-preserving scaffolds that have been validated in multiple clinical settings. Following the US launch of DermaPure®, we expect